Arthritis & Rheumatology · 2022 · 54 citations · 26 references
PharmacyPharmacokineticsPharmacotherapyClinical PharmacologyRenal PharmacotherapyRheumatologyGoutGout PharmacotherapyPharmacokinetics In Renal ImpairmentPharmacologic Management Of GoutAcute Gout Flare TreatmentChronic Gouty ArthritisImmunogenicity EffectsMonitoring Treatment ResponsePrimary Efficacy EndpointsRefractory Gout TreatmentSerum Urate MonitoringTherapy Failure
Objective To assess efficacy, safety, pharmacokinetics, and immunogenicity of pegloticase plus methotrexate (MTX) versus pegloticase plus placebo cotreatment for uncontrolled gout in a randomized, placebo‐controlled, double‐blind trial. Methods This study included adults with uncontrolled gout, defined as serum urate ≥7 mg/dl, oral urate‐lowering therapy failure or intolerance, and presence of ongoing gout symptoms including ≥1 tophus, ≥2 flares in the past 12 months, or gouty arthritis. Key exclusion criteria included MTX contraindication, current immunosuppressant use, G6PDH deficiency, and estimated glomerular filtration rate <40 ml/minute/1.73 m 2 . Patients were randomized 2:1 to 52 weeks of pegloticase (8 mg biweekly) with either oral MTX (15 mg/week) or placebo. The primary end point was the proportion of treatment responders during month 6 (defined as serum urate <6 mg/dl for ≥80% of visits during weeks 20–24). Efficacy was evaluated in all randomized patients (intent‐to‐treat population), and safety was evaluated in all patients receiving ≥1 blinded MTX or placebo dose. Results A total of 152 patients were randomized, 100 to receive pegloticase plus MTX, 52 to receive pegloticase plus placebo. Significantly higher treatment response occurred during month 6 in the MTX group versus the placebo group (71.0% [71 of 100 patients] versus 38.5% [20 of 52 patients], respectively; between‐group difference 32.3% [95% confidence interval 16.3%, 48.3%]) ( P < 0.0001 for between‐group difference). During the first 6 months of pegloticase plus MTX or pegloticase plus placebo treatment, 78 (81.3%) of 96 MTX patients versus 47 (95.9%) of 49 placebo patients experienced ≥1 adverse event (AE), most commonly gout flare (64 [66.7%] of 96 MTX patients and 34 [69.4%] of 49 placebo patients). Reports of AEs and serious AEs were comparable between groups, but the infusion reaction rate was considerably lower with MTX cotherapy (4.2% [4 of 96 MTX patients, including 1 patient who had anaphylaxis]) than with placebo cotherapy (30.6% [15 of 49 placebo patients, 0 who had anaphylaxis]) ( P < 0.001). Antidrug antibody positivity was also lower in the MTX group. Conclusion MTX cotherapy markedly increased pegloticase response rate over placebo (71.0% versus 38.5%) during month 6 with no new safety signals. These findings verify higher treatment response rate, lower infusion reaction incidence, and lower immunogenicity when pegloticase is coadministered with MTX.
26
Measurement of patient outcome in arthritis
James F. Fries, Patricia W. Spitz, R. Guy Kraines et al. · Arthritis & Rheumatism · 1980 · 4.4K citations
Hugh A. Sampson, Anne Muñoz‐Furlong, Ronna L. Campbell et al. · Journal of Allergy and Clinical Immunology · 2006 · 2.3K citations
Dinesh Khanna, Puja Khanna, John FitzGerald et al. · Arthritis Care & Research · 2012 · 731 citations · Full text
Independent Impact of Gout on Mortality and Risk for Coronary Heart Disease
Hyon K. Choi, Gary C. Curhan · Circulation · 2007 · 663 citations · Full text